Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...
Tether Holdings Ltd., the stablecoin issuer that was pulled into the spotlight this week during the confirmation hearing for ...
In a report released yesterday, C J Muse from Cantor Fitzgerald maintained a Hold rating on KLA (KLAC – Research Report), with a price target ...
Cantor Fitzgerald analyst Thomas Blakey reiterated a Hold rating on Atlassian (TEAM – Research Report) yesterday and set a price target of ...
Howard Lutnick, chairman and CEO of investment firms Cantor Fitzgerald and BGC Group, told the U.S. Senate Committee on ...
Howard Lutnick, Trump’s pick for Commerce Department head, told senators Wednesday he'll crack down on those who treat the ...
Secretary of Commerce-designate Howard Lutnick told a Senate committee that the threat of imposing a 25% tariff was to get ...
Billionaire financier Howard Lutnick, President Donald Trump's choice to lead the Commerce Department, said Wednesday that he ...